PCRXPacira BioSciences, Inc.
Is the business good?
The checks split: nothing decisive, though margins compressing.
Operating margin has narrowed over the past few years, profitability per dollar of sales is eroding.
A balanced mix of margins, efficiency, and leverage. ROE 2% = margin × turnover × leverage.
All from derived.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is PCRX?
Pacira BioSciences, Inc. earns 2.0% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
Return on invested capital · cost of capital 9.0% · 7.0 points below what the capital costs: growth destroys value
- Operating margin
- 2.7%
Operating margin · Drug Manufacturers - Specialty & Generic median 11% · 12 months to Q2 2026
- Share count, year on year
- −11%
Share count, year on year · bought back, each share owns more of the company
- R&D as % of revenue
- 16%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | 11% |
| FY2021 | 17% |
| FY2022 | 9.0% |
| FY2023 | 13% |
| FY2024 | −10% |
| FY2025 | 2.6% |
Details›
- Gross margin12 months to Q2 2026
- 79%
- Operating margin12 months to Q2 2026
- 2.7%
- Net margin12 months to Q2 2026
- 2.0%
- Free cash flow margin
- 24%
- R&D as % of revenue
- 16%
- Revenue, trailing twelve months
- $746M
- Free cash flow, trailing twelve months
- $180M
- Net income, trailing twelve months
- $15M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 2.0%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Drug Manufacturers, Specialty & Generic
Ranks #19 of 41 by RyuScore